vs
Side-by-side financial comparison of Jazz Pharmaceuticals plc (JAZZ) and PERRIGO Co plc (PRGO). Click either name above to swap in a different company.
Jazz Pharmaceuticals plc is the larger business by last-quarter revenue ($1.2B vs $1.1B, roughly 1.1× PERRIGO Co plc). Jazz Pharmaceuticals plc runs the higher net margin — 17.0% vs -127.8%, a 144.8% gap on every dollar of revenue. On growth, Jazz Pharmaceuticals plc posted the faster year-over-year revenue change (10.1% vs -2.5%). Jazz Pharmaceuticals plc produced more free cash flow last quarter ($345.8M vs $148.6M). Over the past eight quarters, Jazz Pharmaceuticals plc's revenue compounded faster (15.2% CAGR vs 1.3%).
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
Perrigo Company plc is an American Irish-registered manufacturer of private label over-the-counter pharmaceuticals, and while 70% of Perrigo's net sales are from the U.S. healthcare system, Perrigo is legally headquartered in Ireland for tax purposes, which accounts for 0.60% of net sales. In 2013, Perrigo completed the sixth-largest US corporate tax inversion in history when it reregistered its tax status to Ireland to avoid U.S. corporate taxes. Perrigo maintains its corporate headquarters ...
JAZZ vs PRGO — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.2B | $1.1B |
| Net Profit | $203.5M | $-1.4B |
| Gross Margin | — | 32.6% |
| Operating Margin | 21.2% | -116.0% |
| Net Margin | 17.0% | -127.8% |
| Revenue YoY | 10.1% | -2.5% |
| Net Profit YoY | 6.5% | -3093.9% |
| EPS (diluted) | $3.34 | $-10.23 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.2B | $1.1B | ||
| Q3 25 | $1.1B | $1.0B | ||
| Q2 25 | $1.0B | $1.1B | ||
| Q1 25 | $897.8M | $1.0B | ||
| Q4 24 | $1.1B | $1.1B | ||
| Q3 24 | $1.1B | $1.1B | ||
| Q2 24 | $1.0B | $1.1B | ||
| Q1 24 | $902.0M | $1.1B |
| Q4 25 | $203.5M | $-1.4B | ||
| Q3 25 | $251.4M | $7.5M | ||
| Q2 25 | $-718.5M | $-8.4M | ||
| Q1 25 | $-92.5M | $-6.4M | ||
| Q4 24 | $191.1M | $-44.4M | ||
| Q3 24 | $215.1M | $-21.0M | ||
| Q2 24 | $168.6M | $-108.4M | ||
| Q1 24 | $-14.6M | $2.0M |
| Q4 25 | — | 32.6% | ||
| Q3 25 | — | 36.1% | ||
| Q2 25 | — | 34.4% | ||
| Q1 25 | — | 37.6% | ||
| Q4 24 | — | 33.9% | ||
| Q3 24 | — | 37.2% | ||
| Q2 24 | — | 37.0% | ||
| Q1 24 | — | 33.1% |
| Q4 25 | 21.2% | -116.0% | ||
| Q3 25 | 5.1% | 7.0% | ||
| Q2 25 | -65.6% | 4.3% | ||
| Q1 25 | -6.2% | 4.5% | ||
| Q4 24 | 17.5% | 10.0% | ||
| Q3 24 | 24.7% | 7.4% | ||
| Q2 24 | 19.5% | -2.5% | ||
| Q1 24 | 7.3% | -5.1% |
| Q4 25 | 17.0% | -127.8% | ||
| Q3 25 | 22.3% | 0.7% | ||
| Q2 25 | -68.7% | -0.8% | ||
| Q1 25 | -10.3% | -0.6% | ||
| Q4 24 | 17.6% | -3.9% | ||
| Q3 24 | 20.4% | -1.9% | ||
| Q2 24 | 16.5% | -10.2% | ||
| Q1 24 | -1.6% | 0.2% |
| Q4 25 | $3.34 | $-10.23 | ||
| Q3 25 | $4.08 | $0.05 | ||
| Q2 25 | $-11.74 | $-0.06 | ||
| Q1 25 | $-1.52 | $-0.05 | ||
| Q4 24 | $2.97 | $-0.32 | ||
| Q3 24 | $3.42 | $-0.15 | ||
| Q2 24 | $2.49 | $-0.79 | ||
| Q1 24 | $-0.23 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.4B | — |
| Total DebtLower is stronger | $5.4B | — |
| Stockholders' EquityBook value | $4.3B | $2.9B |
| Total Assets | $11.7B | $8.5B |
| Debt / EquityLower = less leverage | 1.24× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.4B | — | ||
| Q3 25 | $1.3B | $432.1M | ||
| Q2 25 | $1.2B | $454.2M | ||
| Q1 25 | $1.9B | $409.9M | ||
| Q4 24 | $2.4B | $558.8M | ||
| Q3 24 | $2.2B | $1.5B | ||
| Q2 24 | $1.4B | $542.8M | ||
| Q1 24 | $1.4B | $658.5M |
| Q4 25 | $5.4B | — | ||
| Q3 25 | $5.4B | — | ||
| Q2 25 | $5.4B | — | ||
| Q1 25 | $5.4B | — | ||
| Q4 24 | $6.1B | — | ||
| Q3 24 | $6.1B | — | ||
| Q2 24 | $5.7B | — | ||
| Q1 24 | $5.7B | — |
| Q4 25 | $4.3B | $2.9B | ||
| Q3 25 | $4.0B | $4.4B | ||
| Q2 25 | $3.7B | $4.5B | ||
| Q1 25 | $4.2B | $4.4B | ||
| Q4 24 | $4.1B | $4.3B | ||
| Q3 24 | $4.2B | $4.6B | ||
| Q2 24 | $3.8B | $4.5B | ||
| Q1 24 | $3.7B | $4.7B |
| Q4 25 | $11.7B | $8.5B | ||
| Q3 25 | $11.4B | $10.1B | ||
| Q2 25 | $10.9B | $10.1B | ||
| Q1 25 | $11.5B | $9.8B | ||
| Q4 24 | $12.0B | $9.6B | ||
| Q3 24 | $12.3B | $11.2B | ||
| Q2 24 | $11.4B | $10.4B | ||
| Q1 24 | $11.3B | $10.6B |
| Q4 25 | 1.24× | — | ||
| Q3 25 | 1.35× | — | ||
| Q2 25 | 1.45× | — | ||
| Q1 25 | 1.29× | — | ||
| Q4 24 | 1.49× | — | ||
| Q3 24 | 1.47× | — | ||
| Q2 24 | 1.52× | — | ||
| Q1 24 | 1.54× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $362.5M | $175.4M |
| Free Cash FlowOCF − Capex | $345.8M | $148.6M |
| FCF MarginFCF / Revenue | 28.9% | 13.4% |
| Capex IntensityCapex / Revenue | 1.4% | 2.4% |
| Cash ConversionOCF / Net Profit | 1.78× | — |
| TTM Free Cash FlowTrailing 4 quarters | $1.3B | $145.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $362.5M | $175.4M | ||
| Q3 25 | $474.6M | $51.7M | ||
| Q2 25 | $88.9M | $75.9M | ||
| Q1 25 | $429.8M | $-64.5M | ||
| Q4 24 | $398.6M | $312.6M | ||
| Q3 24 | $398.7M | $42.2M | ||
| Q2 24 | $331.4M | $9.5M | ||
| Q1 24 | $267.2M | $-1.4M |
| Q4 25 | $345.8M | $148.6M | ||
| Q3 25 | $459.4M | $29.8M | ||
| Q2 25 | $75.9M | $56.7M | ||
| Q1 25 | $415.9M | $-90.0M | ||
| Q4 24 | $385.3M | $274.9M | ||
| Q3 24 | $388.0M | $15.1M | ||
| Q2 24 | $324.3M | $-18.9M | ||
| Q1 24 | $260.3M | $-26.5M |
| Q4 25 | 28.9% | 13.4% | ||
| Q3 25 | 40.8% | 2.9% | ||
| Q2 25 | 7.3% | 5.4% | ||
| Q1 25 | 46.3% | -8.6% | ||
| Q4 24 | 35.4% | 24.2% | ||
| Q3 24 | 36.8% | 1.4% | ||
| Q2 24 | 31.7% | -1.8% | ||
| Q1 24 | 28.9% | -2.4% |
| Q4 25 | 1.4% | 2.4% | ||
| Q3 25 | 1.3% | 2.1% | ||
| Q2 25 | 1.2% | 1.8% | ||
| Q1 25 | 1.5% | 2.4% | ||
| Q4 24 | 1.2% | 3.3% | ||
| Q3 24 | 1.0% | 2.5% | ||
| Q2 24 | 0.7% | 2.7% | ||
| Q1 24 | 0.8% | 2.3% |
| Q4 25 | 1.78× | — | ||
| Q3 25 | 1.89× | 6.89× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 2.09× | — | ||
| Q3 24 | 1.85× | — | ||
| Q2 24 | 1.97× | — | ||
| Q1 24 | — | -0.70× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
JAZZ
| Xywav | $465.5M | 39% |
| Total Oncology | $337.8M | 28% |
| Rylaze Enrylaze | $108.2M | 9% |
| Zepzelca | $90.4M | 8% |
| Product And Services Royalties And Contract Revenue | $65.5M | 5% |
| High Sodium AG Oxybate Product Royalty Revenue | $55.7M | 5% |
| Xyrem | $37.8M | 3% |
| Vyxeos | $34.7M | 3% |
| Ziihera | $8.5M | 1% |
| Other Products | $2.8M | 0% |
| Sativex | $1.5M | 0% |
PRGO
| Consumer Self Care Americas | $697.0M | 63% |
| Digestive Health | $123.9M | 11% |
| Nutrition | $108.3M | 10% |
| Healthy Lifestyle | $94.8M | 9% |
| Pain And Sleep Aids | $87.1M | 8% |
